AC Immune SA

AC Immune SA held its Annual General Meeting on June 11, 2026, reviewing its 2025 financial performance, which included an IFRS net loss of CHF 70.4 million, and outlining key strategic achievements and milestones for 2026. The company reported a strong liquidity position of CHF 91.4 million at year-end 2025, extending its cash runway into Q4 2027, and provided a 2026 cash burn guidance of CHF 55-65 million. Shareholders will vote on various proposals, including the approval of financial statements, compensation for the Board and Executive Management, and changes to the Articles of Association regarding capital structure.

AC Immune SA announced it will receive a $4 million research grant from The Vijay and Marie Goradia Charitable Foundation. This grant will fund the extension of Part 1 of the ongoing Phase 2 VacSYn trial for ACI-7104, an active immunotherapy for early Parkinson's disease. The extension will assess the long-term safety and efficacy of the treatment for an additional two years. Final data from Part 1 are anticipated in the second half of 2026. Previous interim results from December 2025 indicated a potential disease-modifying effect and a favorable safety profile.

AC Immune announced new preliminary Phase 1 data for its first-in-class TDP-43 PET tracer ACI-19626, demonstrating significantly higher uptake in key brain regions of patients with amyotrophic lateral sclerosis (ALS) compared to healthy controls. These results, presented at the 2026 TDP43 Summit, build upon previous findings showing detection of TDP-43 in patients with genetic frontotemporal dementia (FTD). The tracer continues to exhibit good safety, tolerability, and a pharmacokinetic profile suitable for human brain imaging, underscoring its potential for early diagnosis and precision medicine in neurodegenerative diseases.

AC Immune SA announced its Annual General Meeting (AGM) for June 11, 2026, where shareholders will vote on key proposals including the approval of 2025 financial statements and changes to the Articles of Association. Dr. Andrea Pfeifer will retire as CEO after 23 years, with Martin Zügel, Chair of the Board, appointed Interim CEO. The company also proposes to introduce a capital band and increase conditional share capital for employee benefit plans. Additionally, AC Immune reported positive clinical progress for its pipeline, including interim results for ACI-7104 in Parkinson's disease and advancement of its NLRP3 inflammasome inhibitor into Phase 1. A strategic review in 2025 resulted in a 30% workforce reduction and extended the cash runway into Q4 2027.

AC Immune SA announced that its co-founder and CEO, Dr. Andrea Pfeifer, will retire from her role at the upcoming Annual General Meeting after 23 years. Dr. Martin Zügel, the current Board Chair, has been appointed interim CEO while the company conducts a search for a permanent successor. Dr. Pfeifer will remain involved as an Advisor, Honorary Chair of the Board, and Co-Chair of the Scientific Advisory Board to facilitate a smooth transition. The company emphasized its strong financial position and pipeline, including three clinical-stage candidates and strategic partnerships.

AC Immune SA reported Q1 2026 financial and corporate updates, highlighting significant progress in its neurodegenerative disease pipeline. The company initiated the final cohort of its ACI-24 trial for Alzheimer's, triggering a $12 million milestone payment from Takeda, and amended its Morphomer Tau collaboration with Lilly, securing a CHF10 million upfront payment. AC Immune also advanced its NLRP3 inhibitor ACI-19764 into Phase 1 clinical development and expects multiple data readouts in 2026. The company's cash resources of CHF 74.8 million are projected to fund operations into Q4 2027, and its net loss improved to CHF 14.8 million in Q1 2026 from CHF 19.0 million in Q1 2025.

AC Immune SA reported a net loss of CHF 14.8 million for Q1 2026, an improvement from CHF 19.0 million in Q1 2025, with cash resources of CHF 74.8 million expected to fund operations into Q4 2027. The company initiated the final AD4 cohort in the ACI-24 ABATE trial, triggering a $12 million milestone payment from Takeda. Additionally, an amended Morphomer® Tau collaboration with Eli Lilly includes a CHF 10 million upfront payment and potential future milestones exceeding CHF 1.7 billion. AC Immune also dosed the first subjects in its Phase 1 trial for NLRP3 inhibitor ACI-19764 and presented promising interim data for ACI-7104 in Parkinson's disease.

AC Immune SA announced the dosing of the first patients in Cohort AD4, the final cohort of its Phase 1b/2 ABATE trial for ACI-24, an active immunotherapy targeting Alzheimer's disease. This milestone triggered a $12 million payment from Takeda under their exclusive partnership agreement. The trial aims to evaluate ACI-24's potential for precision prevention of neurodegenerative diseases, building on encouraging early safety and immunogenicity data from previous cohorts. Data from Cohorts AD1, AD2, and AD3 are anticipated in Q2 2026.